

February 25, 2008

FOR PRIVATE CIRCULATION

Equity

| | 22 Feb 08 | % Chg | | |
|-----------------------|-----------|-------|--------|--------|
| | | 1 Day | 1 Mth | 3 Mths |
| Indian Indices | | | | |
| Sensex | 17,349 | (2.2) | (5.5) | (8.0) |
| Nifty | 5,111 | (1.6) | (5.1) | (8.9) |
| Banking | 10,150 | (3.1) | (10.8) | (2.5) |
| IT | 3,316 | (2.4) | (3.2) | (6.7) |
| Healthcare | 3,745 | 0.3 | 1.4 | (1.7) |
| FMCG | 2,231 | (0.3) | 3.3 | 5.7 |
| PSU | 8,209 | (1.1) | (5.3) | (13.6) |
| CNX Midcap | 7,095 | (1.2) | (6.6) | (7.0) |
| World indices | | | | |
| Nasdaq | 2,303 | 0.2 | (1.0) | (11.3) |
| Nikkei | 13,500 | (1.4) | 1.1 | (7.4) |
| Hangseng | 23,305 | (1.3) | (6.8) | (11.8) |

Value traded (Rs cr)

| | 22 Feb 08 | % Chg - 1 Day |
|-------------|-----------|---------------|
| Cash BSE | 4,638 | (12.0) |
| Cash NSE | 10,201 | (16.3) |
| Derivatives | 36,386.2 | (16.2) |

Net inflows (Rs cr)

| | 21 Feb 08 | % Chg | MTD | YTD |
|-------------|-----------|-------|---------|----------|
| FII | 286 | 404 | 4,890 | (12,338) |
| Mutual Fund | (227) | 19 | (1,088) | 6,491 |

FII open interest (Rs cr)

| | 21 Feb 08 | % chg |
|-------------------|-----------|-------|
| FII Index Futures | 27,761 | 1.5 |
| FII Index Options | 9,947 | 2.5 |
| FII Stock Futures | 28,743 | 2.0 |
| FII Stock Options | 184 | 5.8 |

Advances/Declines (BSE)

| | 22 Feb 08 | A | B1 | B2 | Total | % Total |
|-----------|-----------|-----|-----|-------|-------|---------|
| Advances | 59 | 186 | 214 | 459 | 31 | |
| Declines | 159 | 467 | 375 | 1,001 | 67 | |
| Unchanged | 1 | 10 | 17 | 28 | 2 | |

Commodity

| | 22 Feb 08 | % Chg | | |
|--------------------------|-----------|-------|-------|--------|
| | | 1 Day | 1 Mth | 3 Mths |
| Crude (NYMEX) (US\$/BBL) | 99.5 | 0.7 | 9.7 | 1.4 |
| Gold (US\$/OZ) | 945.2 | (0.1) | 3.7 | 15.0 |
| Silver (US\$/OZ) | 18.0 | 0.8 | 9.7 | 22.3 |

Debt/forex market

| | 22 Feb 08 | 1 Day | 1 Mth | 3 Mths |
|---------------------|-----------|-------|-------|--------|
| 10 yr G-Sec yield % | 7.61 | 7.63 | 7.46 | 7.91 |
| Re/US\$ | 40.05 | 39.93 | 39.49 | 39.53 |

Sensex



Source: Bloomberg

ECONOMY NEWS

- Personal and corporate income tax cuts, excise duty relief and simplification of taxes are expected in the Union Budget for 2008-09, the last full-fledged Budget before the next general elections. (BS)
- The Finance Minister has expressed optimism that indirect tax collections would exceed the Budget target of over Rs.2790 bn for the current fiscal. (ET)
- Budget 2008-09 may provide a bailout package for six labor-intensive sectors. Textiles, gems & jewelry, handloom, handicraft, marine and leather may get excise waivers and an extension of interest rate subvention which expires in March. (ET)
- Ahead of the Sixth Pay Commission report, the RBI has suggested that state Governments should not adopt the Pay Panel recommendations unmindful of their capacity to bear the additional burden. (ET)
- The Finance Ministry has decided against according declared good status to aviation turbine fuel in the Budget. The move would have reduced sales tax on jet fuel to a uniform 4% across the country. (ET)
- The Steel Ministry has recommended that customs duty on chrome ore be made on ad valorem basis of 15-20% in the coming Budget. (ET)

CORPORATE NEWS

- **RIL's** retail arm, Reliance Retail, is locked in 'substantial' discussions to float an equal joint venture with iconic UK fashion retailer Marks & Spencer for apparel, gourmet food and cafes, sources said. (ET)
- The boards of directors of **HDFC Bank** and **Centurion Bank of Punjab** have separately given their in-principle approvals for merger of the two banks. HDFC Bank is expected to pay Rs.100-Rs.120 bn in shares for absorbing CBoP. (BS)
- **Bank of Baroda** has reduced its prime lending rate by 50 basis points to 12.75% to stimulate credit demand. The new rate will be effective February 27 2008. (BS)
- **Tata Motors** is learnt to have kick-started the process of raising nearly \$2.5 bn, mostly from the overseas markets, by giving the mandate to a battery of banks. (ET)
- The Uttar Pradesh Government has seized stocks from three sugar mills owned by **Bajaj Hindusthan** for non-payment of last season's sugarcane price to farmers. (BS)
- Datacom Solutions, in which **Videocon's** Venugopal Dhoot holds a stake, has topped the list of companies in terms of precedence in converting its LoIs into a license, according to a note finalized by DoT. (BS)
- **Maharashtra Seamless** is planning to set up a 1 MT per year billet plant in Maharashtra to feed its planned seamless pipe expansion. (BS)
- **BSE** has agreed to buy a 26% stake in the Ahmedabad-based National **Multi-Commodity Exchange**. (ET)
- Kishore Biyani promoted PE fund Indivision India Partners, which had picked up a 4.9% stake in **Dish TV** for Rs.2.5 bn, has now cancelled the deal. (ET)
- **Future Ventures India Ltd**, the venture capital arm of Kishore Biyani's Future Group, is ready to hit the market with an IPO of around Rs.37.5 bn. (BS)
- **GlaxoSmithKline Pharmaceutical's** net profit stood at Rs.809 mn for the quarter ended December 31 2007, compared with Rs.677.9 mn in the corresponding period of the previous year. (BL)

Source: ET = Economic Times, BS = Business Standard, FE = Financial Express, BL = Business Line, Tol: Times of India, BSE = Bombay Stock Exchange

FROM OUR RESEARCH TEAM

INITIATING COVERAGE

Rohit Ledwani
 rohit.ledwani@kotak.com
 +91 22 6634 1507

Teena Virmani
 teena.virmani@kotak.com
 +91 22 6634 1237

Stock details

| | |
|-----------------------|--------------|
| BSE code | : 532647 |
| NSE code | : PROVOGUE |
| Market cap (Rs mn) | : 20,007 |
| Free float (%) | : 56.4 |
| 52-wk Hi/Lo (Rs) | : 1460 / 431 |
| Avg. daily volume BSE | : 9934 |
| Avg. daily volume NSE | : 15638 |
| Shares o/s (m) | : 19.0 |

Summary table (Rs mn)

| | FY08E | FY09E | FY10E |
|-----------------|-------|-------|-------|
| Sales | 3,326 | 4,677 | 6,220 |
| Growth % | 39.3 | 40.6 | 33.0 |
| EBITDA | 466 | 677 | 940 |
| EBITDA margin % | 14.0 | 14.5 | 15.1 |
| Net profit | 273 | 483 | 713 |
| Net cash (debt) | 503 | 164 | 77 |
| EPS (Rs) | 14.4 | 25.4 | 37.5 |
| Growth % | 39.6 | 76.6 | 47.7 |
| CEPS | 18.2 | 29.7 | 42.5 |
| DPS (Rs) | 2.9 | 5.1 | 7.5 |
| ROE % | 10.0 | 16.0 | 20.5 |
| ROCE % | 13.1 | 18.1 | 23.3 |
| EV/Sales (x) | 6.2 | 4.3 | 3.3 |
| EV/EBITDA (x) | 44.1 | 30.0 | 21.6 |
| P/E (x) | 73.2 | 41.4 | 28.0 |
| P/Cash Earnings | 57.9 | 35.4 | 24.7 |
| P/BV (x) | 7.1 | 6.2 | 5.3 |

Source: Kotak Securities - Private Client Research

PROVOGUE (INDIA) LTD

PRICE : Rs.1053

RECOMMENDATION : BUY

TARGET PRICE : Rs.1360

FY09E PE : 41.4x

Provogue, a leading retailer and manufacturer of lifestyle products, is all set to benefit from the growth in consumerism, higher disposable incomes and increasing penetration of organized retail. Over the past few years the company has built a strong brand synonymous with lifestyle.

The company is on an expansion mode. We expect Provogue to expand its total retail space to 0.5mn sq ft by FY10 as compared to 0.15 mn sq ft in FY07.

The company is also looking to diversify its product portfolio by adding new product lines such as accessories, personal care products, etc. With this, the company is aiming to target a larger wallet share from consumers and leverage on its strong lifestyle brand. The Company has also entered the value retailing format though 'Promart', Provog is looking to target a larger base of customers as well as benefit from the strong growth in this value retailing segment.

Provogue is also leveraging its retailing experience to venture into retail infrastructure development through its subsidiary Prozone Enterprises Pvt Ltd in collaboration with UK-based FTSE-100 company Liberty International Plc. The company plans to develop 16mn sq ft across retail, commercial and hotel segments in its first phase of development. We expect significant benefits to accrue to Prozone due to this joint venture with Liberty.

Going forward, we estimate the company's revenues (standalone) to grow at a CAGR of 37% and PAT at a CAGR of 53% between FY07-FY10. The company's operating margins are also expected to rise to 15% in FY10 as compared to 13.4% in FY07.

We value the standalone business at a P/E multiple of 15(x) our estimated FY10 EPS of 37.6, which gives a value of Rs.564/share. We value the 75% stake in the Prozone subsidiary at Rs.796/share of Provogue based on NPV of the individual projects in retail segment while land value for the hotel and commercial segment is valued according to the current value and discounted by 30%. This gives us a total valuation of Rs. 1360. We recommend investors BUY with a 12 month horizon.

Key investment rationale

- **Organized retail penetration to double over next few years.** According to Crisil, the total size of the retail industry in India is about US\$320 bn, of which only 3-4% is organized. This is expected to more than double and reach approximately 9% by 2011. The organized retail industry is expected to grow at a CAGR of 25-30% over the next few years. Provogue with its expertise in the organized retail industry is well set to capitalize on this growth through its expansion plans into different products and retailing formats.
- **'Provogue' - High brand recall value.** The company's flagship brand 'Provogue' is synonymous with youth, fashion and lifestyle. The stores of the company are located at high street locations and malls and have good penetration pan-India. The brand 'Provogue' has a high recall value and the company enjoys the loyalty of a large base of customers which have helped it grow over the past few years. The brand Provogue was ranked fifth among all consumer brands in a National loyalty survey. We believe that with its strong brand, the company is well placed to counter competition in the sector going forward, as well as be able to expand its offerings to customers.

- ❑ **Retail centric organization.** The company aims to grow by giving the consumer a better retailing experience. With presence in high value retail, value retail and retail infrastructure the company is well placed to extract maximum benefit from the retailing boom being witnessed in India.
- ❑ **Expanding into new products categories.** To grab a greater wallet share of customers, the company has ventured into retailing products such as footwear, bags, belts, accessories, perfumes, personal care products etc. With the brand being synonymous with lifestyle and fashion the company is leveraging it so as to offer the customer a one stop store for lifestyle products.
- ❑ **New format 'Promart' to attract larger customer base.** In order to tap the retail opportunity with the aspirational value conscious consumer, 'Provogue' has recently launched a new format 'Promart' that offers consumers branded products at discounted prices. These are large format stores ranging from 50,000 to 100,000 sq ft and house over 100 brands. These are products of earlier seasons available at low prices. With the company having a brand synonymous with lifestyle, Provogue will benefit to a great extent in this format as it can now tap the lower middle class who aspire to have lifestyle products but are not able to afford them.

With the success of value retailing formats in India we are very positive on 'Promart'. We believe it would contribute significantly to its revenues and net profit, going forward.

- ❑ **Strong like-to-like growth.** Provogue has been adding space rapidly over past few years. As on FY07 the company operated 98 stores spread across 110,000 sq feet. Going forward, we estimate the company to operate 1,75,000 sq feet by FY08 and operate 0.5 mn sq feet by FY10 between Provogue and Promart. This expansion plans will help the company attract new customers and improve like-to-like growth going forward.

The company has been reporting like-to-like sales growth of 22% across all its stores. This is higher than other retailers. With a strong brand, the company has established a loyal base of customers. Provogue was also voted fifth in the brand loyalty survey. This high like-to-like growth also enables the company to expand margins.

- ❑ **Strong supply chain network.** A large portion of the products sold are manufactured by Provogue in-house at its plant located in Daman. The company is also setting up a new plant at Himachal Pradesh so as to have a better control on production, distribution and timing of products to its stores.

The products that the company does not manufacture in-house are designed and distributed by Provogue and only the pure manufacturing is outsourced. Hence, the company has control over its supply chain. Since Provogue has a team of professionals who are in touch with latest fashion the company reduces the risk of fashion redundancy.

- ❑ **Significant value attached to 'Prozone - Retail infrastructure.** Provogue is also leveraging its retailing experience to venture into retail infrastructure development through its subsidiary Prozone Enterprises Pvt Ltd in collaboration with UK-based FTSE-100 company Liberty International Plc. Liberty International has bought 25% stake in Prozone and remaining is owned by Provogue. Prozone intends to develop approximately 16mn sq ft in retail, commercial and hotel segment in its first phase of development planned in Aurangabad, Jaipur, Nagpur and Indore. Going forward, it would be looking at Coimbatore, Lucknow, Jodhpur, Bhopal, Hyderabad, Mysore etc for setting up retail malls. Through this JV, Prozone is well set to capitalize on the parent company as well as Liberty's expertise in the retailing segment. Annual rental revenue streams would also enable the company to convert it finally into REIT.

Prozone would also be looking at fund raising through different means for funding its current projects. Higher than expected valuation for its ongoing projects are expected to provide further positive triggers.

Valuation & recommendation

At the current price the stock is trading at 41.4x and 28x FY09E and FY10E P/E multiples, respectively.

We value the retail business on a P/E multiple of 15x FY10E EPS of Rs.37.6. The multiple is a discount to our multiple for Pantaloons and Vishal Retail. This discount is primarily due to the smaller size of Provogue and the lower growth rates compared to Vishal and Pantaloons.

At our FY10E EPS of Rs.37.6 we value the retail business at Rs.564 per share and value the 75% stake in Prozone at Rs.796/share of Provogue.

We have valued first phase of development for Prozone by arriving at the NPV of the individual projects in retail segment while land value for the hotel and commercial segment is valued as per the current value and discounted by 30%.

This gives us a total valuation of Rs.1360 per share. Hence, we recommend investors BUY with a 12-month price target of Rs.1360.

We initiate coverage with BUY recommendation on Provogue (India) Ltd with a price target of Rs.1360

Key risks and concerns

- ❑ **Too much dependency on brand 'Provogue':** Although the company has created a very strong brand for itself, any loss in brand equity or damage will affect the business of the organization.
- ❑ **Delay in planned expansion:** Any delay in expansion of stores across formats could impact our estimates and would be a downside risk to our recommendation.
- ❑ **Delay in project completion in Prozone:** Any delay in completion of projects in retail segment may correspondingly impact the hotel and commercial development as well as further phases of development. This may have a negative impact on the valuation of Prozone.

RESULT UPDATE

Awadhesh Garg
awadhesh.garg@kotak.com
 +91 22 6634 1406

AVENTIS PHARMA LTD

PRICE : Rs.905
TARGET PRICE : Rs.901

RECOMMENDATION : SELL
CY09E PE : 12.1x

Summary table

| (Rs mn) | CY07 | CY08E | CY09E |
|-------------------|--------|-------|-------|
| Sales | 8,958 | 9,072 | 9,879 |
| Growth (%) | (1.2) | 1.6 | 9.1 |
| EBITDA | 1,898 | 2,019 | 2,233 |
| EBITDA margin (%) | 21.2 | 22.3 | 22.6 |
| Net profit | 1,444 | 1,549 | 1,728 |
| Net Margin (%) | 16.1 | 17.1 | 17.5 |
| EPS (Rs) | 62.7 | 67.3 | 75.0 |
| Growth (%) | (14.7) | 7.3 | 11.6 |
| DPS (Rs) | 16.0 | 16.0 | 16.0 |
| RoE (%) | 21.9 | 20.2 | 19.5 |
| RoCE (%) | 34.5 | 31.6 | 30.3 |
| EV/Sales (x) | 2.0 | 1.6 | 1.3 |
| EV/EBITDA (x) | 9.4 | 7.2 | 5.9 |
| P/E (x) | 14.4 | 13.5 | 12.1 |
| P/BV (x) | 3.2 | 2.5 | 2.2 |

Source: Company & Kotak Securities - Private Client Research

Disappointment continues; downgrade to SELL

- For CY07, net sales declined 1.2% YoY to Rs.8.7 bn due to lower growth in domestic sales and de-growth in exports
- Supply issues of anti-rabies vaccine due to production issues in the manufacturer's plant continue to drag revenues. However, there has been no clarity over the resolution of the problem
- Rupee appreciation against the dollar, switch to local sourcing by some importing countries and reduction in inventories in some importing countries due to business slowdown led the sharp decline in exports
- EBITDA margins declined sharply due to rise in staff cost and other operating expenses. Net profit declined 14.7% to Rs.1.4 bn due to contraction in margins
- The management has not clarified any of the issues (except currency appreciation), their magnitude and expected timeline for their resolution or reversal, which is a cause for concern
- We are downgrading our EPS estimates by 17% and 19% to Rs.67.3 and Rs.75 for CY08 and CY09, respectively. We downgrade the stock from **HOLD** to **SELL** and close our call on the stock.

Decline in exports and rabies vaccines sales affected overall revenue growth

Aventis has posted poor results for Q4 and CY07 at both revenue and net profit level. For the financial year 2007, net sales declined 1.2% to Rs.8.7 bn. This was affected by lower-than-expected growth in domestic sales and 25% de-growth in exports sales. In Q4CY07, net sales de-grew 6.3% to Rs.2.0 bn as compared to Rs.2.2 bn in Q4CY06.

In CY07, domestic formulation sales grew just 6.8% to Rs.7.0 bn while exports dipped 24.5% to Rs.1.7 bn. During the quarter and financial year of 2007, the company received significantly lower supplies of anti-rabies vaccine Rabipur due to production issues in the manufacturer's plant because of which the expected growth in the Rabipur distribution business could not be achieved. This has resulted in significantly lower sales for the company. Exports for the quarter and full year 2007 were impacted by the appreciation of the rupees vis-à-vis the US dollar, the preferences given by some importing countries to locally manufactured products and the reduction in inventories in some importing countries due to decline in their business performance.

Financial Performance (Q4CY07)

| (Rs mn) | Q4CY07 | Q4CY06 | YoY (%) | Q3CY07 | QoQ (%) | CY07 | CY06 | YoY (%) |
|-------------------|-------------|-------------|--------------|-------------|--------------|-------------|-------------|--------------|
| Net Sales | 2040 | 2176 | -6.3 | 2264 | -9.9 | 8735 | 8840 | -1.2 |
| Expenditure | 1750 | 1749 | | 1818 | | 7060 | 6605 | |
| EBIDTA | 290 | 427 | -32.1 | 446 | -35.0 | 1675 | 2235 | -25.1 |
| Depreciation | 46 | 51 | | 47 | | 185 | 179 | |
| EBIT | 244 | 376 | -35.1 | 399 | -38.8 | 1490 | 2056 | -27.5 |
| Interest | 0 | 1 | | 2 | | 2 | 2 | |
| Other Income | 182 | 111 | | 176 | | 740 | 443 | |
| Tax | 156 | 139 | | 205 | | 784 | 804 | |
| PAT | 270 | 347 | -22.2 | 368 | -26.6 | 1444 | 1693 | -14.7 |
| EPS (Rs) | 11.7 | 15.1 | -22.2 | 16.0 | -26.6 | 62.7 | 73.5 | -14.7 |
| EBIDTA Margin (%) | 14.2 | 19.6 | | 19.7 | | 19.2 | 25.3 | |
| PAT Margin (%) | 13.2 | 15.9 | | 16.3 | | 16.5 | 19.2 | |

Source: Company

We expect the domestic formulation sales to grow at 10% CAGR over the next two years. However, we expect around 2-5% growth in exports sales over the same period. Exports accounted for about 20% of total sales in CY07 and dipped 25%. Most of the exports are to group companies (mainly to the CIS and EU countries), either formulations or intermediates. This reduced their sourcing due to slowdown in their business.

Sales Break-up (Q4CY07)

| | Q4CY07 | Q4CY06 | CY07 | CY06 |
|-----------------------------|-------------|-------------|-------------|-------------|
| Domestic Sales (Net) | 1709 | 1540 | 7031 | 6582 |
| % Net Sales | 83.8 | 70.8 | 80.5 | 74.5 |
| % Growth Y-o-Y | 11.0 | 6.5 | 6.8 | 13.7 |
| Exports Sales | 331 | 636 | 1704 | 2258 |
| % Net Sales | 16.2 | 29.2 | 19.5 | 25.5 |
| % Growth Y-o-Y | (48.0) | 24.5 | (24.5) | (1.3) |
| Net Sales | 2040 | 2176 | 8735 | 8840 |

Source: Company

EBITDA margin declined sharply due to rise in overall costs

EBITDA margin for the year was down 420 bps to 21.7% as staff cost and operating expenses has risen significantly. We believe there was some impact of increased Lantus sales, which has significantly lower gross margin (~14%). The low gross margin is a result of the product being under price control, whereby it only gets a 50% markup over imported price. However, the company is reimbursed certain marketing costs from the parent, which helps shore up the operating margin of this product. Net profit after tax de-grew 14.7% at Rs.1.4 bn as compared to Rs.1.7 bn in CY06, mainly due to sharp decline in the EBITDA margin.

Strategic brands to drive growth in domestic market

Aventis has classified certain brands as strategic, based on the parent's strength in R&D and marketing, which can be leveraged to improve sales growth and margins. These strategic brands are key growth drivers in the domestic market in domestic formulations and constitute over 30% of the company's domestic sales. We understand that all these brands are doing well. We expect these same brands to continue to drive growth. The company expects Lantus to be its largest brand in three to four years, the world's first and only once-daily twenty-four hour basal insulin. However, insulin is under price control. This being an imported drug, we estimate gross margins of 15%.

Parent's global R&D pipeline may benefit Aventis in the long run

Sanofi Aventis globally has 127 new drug discovery projects in the research and development pipeline. This pipeline includes about 45 drugs in pre-clinical development, 26 in phase-I, 38 in phase-II and 18 in late stage development, that is, phase-III. It plans to file about 11 ANDAs and seven vaccines by CY08E. Although clarity on the launch of these drugs will emerge only over a period of time, we believe some of these products could be relevant for the Indian markets and are likely to be launched in India with a time lag.

Sanofi-Aventis Global R&D pipeline

| No. of Drgus | Pre-Clinicals | Phase-I | Phase-IIA | Phase-IIB | Phase-III | Total |
|------------------------|---------------|-----------|-----------|-----------|-----------|------------|
| Cardiovascular | 5 | 3 | 2 | 4 | 1 | 15 |
| Thrombosis | 4 | 1 | 1 | 3 | 1 | 10 |
| Central Nervous System | 10 | 6 | 3 | 2 | 7 | 28 |
| Oncology | 7 | 4 | 3 | 1 | 4 | 19 |
| Metabolic Disorders | 4 | 4 | 3 | 2 | 1 | 14 |
| Internal Medicine | 6 | 6 | 4 | 2 | 2 | 20 |
| Vaccines | 9 | 2 | 4 | 4 | 2 | 21 |
| Total | 45 | 26 | 20 | 18 | 18 | 127 |

Source: Sanofi Aventis Global Annual Report 2005

Valuation & recommendation

We have revised our revenue and earning estimates downward for CY08 and CY09 due to the poor performance in CY07. The key reasons for revision in our estimates were lower supplies of anti-rabies vaccines due to production issues in the Novartis JV and lower-than-expected exports growth.

We believe the issues which resulted in poor performance in 2007 still exist. The management has not clarified any of the issues, their magnitude and expected timeline for their resolution or reversal. This is a cause of concern for us.

We now expect net sales growth of 1.6% and 9.1% and earnings growth of 7.3% and 11.6%, in CY08 and CY09, respectively. We are downgrading our EPS estimates by 17% and 19% to Rs.67.3 and Rs.75 for CY08 and CY09, respectively.

At the current market price of Rs.905, the stock is trading at 13.5x CY08 and 12.1x CY09 earning estimates. The stock has witnessed significant contraction in P/E multiple mainly due to shrinkage in margins and farther visibility for revenue growth. We are downgrading stock from **HOLD** to **SELL** and close our call on the stock with a one-year target price of Rs.901 based on 12x PE multiple to CY09 earnings.

We recommend SELL on Aventis Pharma and close our call with a price target of Rs.901


Key downside risks

- Possibility of new products launches through Sanofi's unlisted Indian subsidiary.
- Risk of likely termination of Chiron Behring JV owing to acquisition of Chiron Vaccines by Novartis.
- Slowdown or price control in domestic formulation market.

Key upside risks

- New products launches through listed entity because Aventis' inherent marketing strengths, in our view, may make it the preferred vehicle for such launches.
- The company is sitting on huge cash (Rs.220/share) and any announcement for buy back of shares or acquisition may provide the stock a boost.

PE Band



Source: Capitaline, Kotak Securities - Private Client Research

EVENT UPDATE

Saurabh Gurnurkar
saurabh.gurnurkar@kotak.com
+91 22 66341273

ENTERTAINMENT NETWORK INDIA LTD (ENIL)

PRICE : Rs.478
TARGET PRICE : Rs.585

RECOMMENDATION : BUY
FY09E: EV/EBITDA: 16x

Trai suggests permission for news/current affairs, higher foreign investment caps, multiple channel ownerships and network linkages, among other recommendations for the FM radio industry.

Trai recommendations on FM radio meet long standing industry expectations. If and when accepted they will likely provide impetus to the fast growing FM radio industry.

We reiterate our preference for market leaders - ENIL, with its dominant positioning, execution ability and growing scale in the outdoor segment i.e. a play on growing urban infrastructure remains a BUY, with an unchanged price target of Rs.585.

Summary table

| (Rs mn) | FY08E | FY09E | FY10E |
|-----------------|-------|-------|-------|
| Sales | 4,498 | 6,504 | 8,089 |
| Growth % | 91.3 | 44.6 | 24.4 |
| EBITDA | 468 | 1,503 | 2,193 |
| EBITDA margin % | 10.4 | 23.1 | 27.1 |
| Net profit | (11) | 711 | 1,088 |
| Net cash (debt) | 1,520 | 598 | 294 |
| EPS (Rs) | -0.2 | 14.9 | 22.9 |
| Growth % | - | - | 53.0 |
| CEPS | 3.4 | 21.3 | 29.6 |
| DPS (Rs) | 0.5 | 1.0 | 1.5 |
| ROE % | -0.4 | 22.2 | 27 |
| ROCE % | 3.1 | 22.5 | 33.5 |
| EV/Sales (x) | 5.4 | 3.6 | 2.9 |
| EV/EBITDA (x) | 51.3 | 15.9 | 10.6 |
| P/E (x) | - | 32.0 | 20.9 |
| P/Cash Earnings | 142.2 | 22.5 | 16.1 |
| P/BV (x) | 7.9 | 6.4 | 5.0 |

Source: Company & Kotak Securities - Private Client Research

- Trai has come out with a set of recommendations, according to news reports, regarding the FM radio industry, which will lead to greater scope for variety in content, higher foreign investment caps, multiple channel ownerships and linking of networks among other things. These recommendations now await the I&B Ministry's formal approval.
- The industry has reacted favorably to Trai's recommendations, which meet some of its long-standing demands like permission for broadcast of news/current affairs and multiple station ownership in the same city.
- We opine that these recommendations are positive and will provide impetus for the fast growing FM radio industry that is expected to grow to Rs.17 bn by 2011E from the current Rs.5 bn odd, according to FICCI-PwC's industry report.
- Below, we have tabulated some of the recommendations of Trai, on the FM radio industry and attempted to analyze their impact on industry players. Significant industry players include ENIL (under the brand Radio Mirchi), Adlabs Radio ('BIG 92.7'), Radio City, HT Media (Fever 104), Red FM and the Sun network.

Likely impact of Trai recommendations

| Issue | Existing Norm | TRAI's recommendation | Impact |
|------------------------------------|---|---|---|
| Content | Broadcast of news/current affairs not permitted. | Broadcast of news capsules be Content to be sourced from AIR, DD, authorized news channels or agencies like PTI & UNI. | Opportunity for players to diversify programming content and reach out to newer markets. |
| Foreign Investment | Uniform 20% FDI cap for all players. | Cap be raised to 26%, in case of news and current affairs channels. Cap to be raised to 49% for non-newschannels. | Player expansion plans, could get a fillip with access to capital and possible strategic business partners. |
| Inter-city networking | No permission for private FM broadcasters to link networks across cities. | Permission to do the same. | Likely positive for player cost structures. |
| Multiple channel ownerships | Each player limited to one station in an operating area. | Same operator be allowed to run multiple radio stations in an operating area. given atleast three other operators in the area in addition to AIR. | Scope for same operator to provide varied content to different segments within a target market. Opportunity for specialised programming genres to emerge. |
| License purview | Currently, licenses are issued city wise | Permission to these being issued district-wise. | Enhancement in area of operation and greater population coverage-larger markets for players. |

Source: Industry, Kotak Securities - Private Client Research

- In addition to these measures Trai has recommended measures like a withdrawal of ceiling on the number of FM radio stations a company can own. According to existing rules, no single FM player can own more than 15% of total FM channels in the country. Ideally, this should lead to FM operators bidding for more stations. In our opinion though, the relatively small ad market sizes in Tier III cities may preclude excessive bidding by rational players.
- The TRAI has also recommended that renewal of the licenses (issued initially for a 10 year period) be renewable for the operator at an entry fee equal to the highest OTEF (one time entry fee) paid in the circle.
- So far, the government has issued 266 FM radio licenses, of which 183 are operational. ENIL, the company under our coverage has rolled out all its allotted 32 stations.
- In our opinion, these recommendations, if implemented, will support the growth of India's FM radio industry. On an industry level, we have consistently outlined the profitability challenges that will be faced by players who have bid uneconomically and more so in smaller centers that have small market sizes. Our preference lies with dominant players with a well diversified footprint and strong executors, like ENIL.
- Within our coverage universe- ENIL and HT Media are companies that have a presence in radio. ENIL with its dominant positioning, optimal selection strategy, and market leadership is possibly best placed to leverage the industry growth. HT's 'Fever 104', on the other hand, with its niche positioning and metro presence will also be a value adder for its parent - HT Media, in our opinion.
- We leave financial estimates unchanged for both stocks. We continue to rate **ENIL as a BUY** (PT: Rs.585) and **HT Media as a HOLD** (PT: Rs.230).
- We have favored ENIL in the media space on account of its dominant position in the radio segment, its emergence as a strong organized player in the nascent OoH space, the strong management and its formidable positioning as a cross-media entity. The stock has also seen a sharp run-up and has appreciated more than 2x since the initiation of our coverage in Q3FY07.

ENIL - Company financials

- ENIL's revenues are expected to grow at a CAGR of 66% over FY07-09E to Rs.6.5 bn in FY09E driven by a robust 33% CAGR growth in radio revenues to Rs.3 bn (Rs.2.93 bn earlier) and a healthy ramp up in TIMPL revenues to Rs.3.5 bn by FY09E.
- Healthy revenue growth, aided by economies of scale emerging across the different business, is expected to impact operating margins positively.
- PAT growth in performance is also to be impacted favorably in FY09 on account of retirement of debt, on account of equity infusion (Rs.2 bn) in the OoH business.
- We consequently expect ENIL to report consolidated profits of Rs.711 mn in FY09E translating into an EPS of Rs.15 over the fiscal.

Valuation & Recommendation

- We have valued ENIL using relevant EV/EBITDA multiples for the different businesses - radio, OoH and Events. We value OoH at Rs.198 per ENIL share. The other businesses, radio and events contribute Rs.383 (radio) and Rs.17 (events, Rs.15 earlier) to our SoTP.
- Summing the above we arrive at a price target of Rs.585 for the stock, based on FY09E earnings. At current levels, the stock trades at 15x FY09E EV/EBITDA and 10x FY10E EV/EBITDA.
- Recent capital raising in OoH values the business at Rs.220 per share. We will await further visibility to roll over our valuations to FY10. At the same time, we note fresh order accretion to the OoH/events order book will be positive for financials.
- Margin erosion in radio, given the high competition and execution slippages across different segments could be key downside risks to our estimates.

ENIL - Company revenues to be split between radio and OoH

- We opine that the radio market has grown with the entry of competition which is reflected in the growing inventory utilization of the major players. Private FM is expected to be slightly more than Rs.5 bn for the fiscal and is expected to sustain its high growth rates, in excess of 45% in the medium term. ENIL currently has 50% in value terms, of the market. In our opinion, ENIL will clock a market share in excess of 40% in the medium term, factoring in competition.
- On an existing station basis, comparing 10 old stations YoY, we estimate that the revenues would have grown 12-13% YoY in Q3FY08. Inventory and utilization have grown at much higher rates; the pricing dip though has muted the value growth for the company.
- This 'value' growth rate in our opinion reflects the competition in radio markets with the entry of new players. We also note Radio Mirchi's continued dominance in terms of listenership in its markets as evidenced by the recently released data and the company's ability to hold and build on its ad rate.
- The push in revenues (DIAL and MIAL), in the OoH business though is expected to come H2 onwards as revenues pick up with a slight lag. Increased revenue contribution in FY09 is expected to improve TIMPL profitability going ahead, in our opinion.

Low operating cost nature in radio, maturing of past investments (OoH and radio) and operating leverage to drive margin productivity, going forward.

- Strong EBITDA% improvement is expected given the low operating costs and consequent leverage on a growing revenue base; typical of radio broadcasting services.
- Radio EBITDA margins are expected to increase to 31% in FY09E from the 23.9% reported in FY08E on account of operating leverage we estimate in the radio business.
- We see significant operating leverage in a mature radio station due to the low cost nature of the business model and see upsides to our radio profitability in the longer term, given good execution.
- We opine the expected slip in TIMPL profitability during 9MFY08 was due to continued investments in the OoH segment and expect EBITDA margins to improve in FY09 as revenues are accrued from the newly acquired properties. (Costs incurred without any corresponding revenue accrual, which is expected, going forward).
- Given the healthy revenue growth expected, radio's low operating costs and past investments maturing in TIMPL we expect consolidated operating margins for ENIL to expand to 23.1% in FY09E, from the 18.2% reported in FY07.

Key Concerns

- Competition and possible irrational behavior of new entrants
- Royalty issues: Currently, radio broadcasters are required to pay a fixed Rs.5 mn in royalties per station per annum irrespective of the station's location. ENIL currently pays about Rs.300-1200/hr for the content played by it to the content owner and also the Phonographic Performance Society (PPL).
- Losses in new properties- radio & OoH

Sum of the parts Valuation (SoTP) of ENIL

| | FY09E | Comments |
|-----------------------------------|--------------|--|
| Radio Business | | |
| EBITDA, Rs.mn | 913.6 | DCF: Radio's standalone DCF-based fair value is Rs.383 with a WACC of 13.2% and terminal growth of 4%. We roll over our DCF base to FY10 leading to the increase in per share value from radio business. |
| | 18231 | |
| EV/share | 383 | |
| OoH-Outdoor Business | | |
| Using EV/EBITDA multiples | | We continue to value the business using relevant EV/EBITDA multiples, will await further visibility to roll over to FY10 earnings. Our fair value sits at Rs.198 per share. |
| EBITDA | 523.4 | |
| Target EV/EBITDA multiple | 18.0 | |
| Target EV | 9421.0 | Recent stake sale to investors values the business at Rs.12bn; ENIL now holds 84% of the OoH arm. |
| EV/share | 198.1 | According to the transaction, value of OoH business translates to Rs.220 per ENIL share |
| 360 Degree-Events Business | | |
| EBITDA | 66.0 | |
| Target EV/EBITDA multiple | 12.0 | Multiple in line with international peers and the steady growth nature of business. |
| Target EV | 792.0 | |
| EV/share | 16.7 | |
| Consolidated EV | | |
| Total EV | 28,443.8 | |
| Less Net debt | 598.0 | Arrived fair value, based on FY09 earnings. |
| Net EV | 27,846 | Reiterate BUY, with a price target of Rs.585. |
| Total EV/Share | 585 | If the OoH stake sale is factored, the fair value would sit at Rs.608. BUY |

Source: Company, Kotak Securities - Private Client Research

Bulk deals

| Trade details of bulk deals | | | | | |
|------------------------------------|-------------------|--|----------------------|-------------------------------|----------------------------|
| Date | Scrip name | Name of client | Buy/ Sell | Quantity of shares | Avg. Price (Rs) |
| 22-Feb | Action Fin | PKJ Share Broker Ltd | B | 98,100 | 41.87 |
| 22-Feb | Action Fin | Uma Songal | S | 50,001 | 41.82 |
| 22-Feb | Allcargo Glo | Blackstone GPV Capital Partners Mauritius V A Limited | B | 730,731 | 824.93 |
| 22-Feb | Allcargo Glo | Reliance Capital Trustee Co Ltd Ac Reliance Growth Fund | S | 321,177 | 825.00 |
| 22-Feb | Allcargo Glo | New Vernon Private Equity Limited | S | 242,000 | 825.00 |
| 22-Feb | Amrit Corp | Dhirendra B Sanghavi | B | 75,433 | 95.15 |
| 22-Feb | Amrit Corp | Bhupendra G Sanghavi | S | 75,333 | 95.15 |
| 22-Feb | Anjani Synth | Ankit Narendra Bahuva | B | 60,058 | 52.55 |
| 22-Feb | Anuh Pharma | Prafulla L. Shah | B | 80,000 | 240.59 |
| 22-Feb | Anuh Pharma | Lalit P. Shah | S | 80,000 | 240.51 |
| 22-Feb | Axon Infotec | Shailendra S Nahar | B | 5,000 | 50.50 |
| 22-Feb | Axon Infotec | Sheetal Kashiram Kadam | S | 5,000 | 50.50 |
| 22-Feb | Birla Power | Lionhart Investments Ltd | | | |
| | | Ac Photon Mauritius Ltd | B | 541,883 | 36.80 |
| 22-Feb | Birla Power | BNP Paribas Arbitrage | S | 547,920 | 36.80 |
| 22-Feb | Chandrik Tra | Isabelle Traders Ltd | S | 150,000 | 3.50 |
| 22-Feb | Choic Intern | Signora Finance Pvt Ltd | B | 100,000 | 16.32 |
| 22-Feb | Cybermat Inf | Pravinsinh Hasmukhlal Vaghela | S | 1,330,722 | 9.60 |
| 22-Feb | Evinix | Anand Yogesh Share and Cons | S | 72,500 | 151.00 |
| 22-Feb | Inca Finleas | Premji Bhuralal Gala | S | 20,000 | 137.70 |
| 22-Feb | Jindal Polfm | Forex Finance Ltd. | B | 230,000 | 230.50 |
| 22-Feb | Jindal Polfm | Bindal Lefin Pvt. Ltd. | S | 230,000 | 230.50 |
| 22-Feb | Jumbo Bag Lt | Gorantla Govindaiah | S | 52,614 | 44.36 |
| 22-Feb | Khaitan Wvg | Avinash Arvind Jagushte | B | 3,726 | 68.30 |
| 22-Feb | KLG Capi Ser | Hemant R Patel HUF | B | 49,444 | 32.76 |
| 22-Feb | KLG Capi Ser | Awaita Properties Private Limited | B | 95,015 | 33.50 |
| 22-Feb | KLG Capi Ser | VSK Infotech Private Limited | S | 107,500 | 32.70 |
| 22-Feb | KLG Capi Ser | Vikas Garg | S | 60,000 | 33.26 |
| 22-Feb | KLG Capi Ser | Dinesh Kumar | S | 30,000 | 33.50 |
| 22-Feb | KLG Capi Ser | Ramesh Kumar | S | 55,000 | 32.73 |
| 22-Feb | Kopran Ltd. | Sangunity Trading Co Pvt Ltd | B | 450,000 | 24.10 |
| 22-Feb | Kopran Ltd. | Saroj Plantations Pvt Ltd | S | 450,000 | 24.10 |
| 22-Feb | Kulk Pow Too | Bhupesh Kumar Lodha | S | 27,000 | 118.41 |
| 22-Feb | Multi Arc In | Jajoo Vimla | B | 200,000 | 28.00 |
| 22-Feb | Multi Arc In | Jajoo Suresh | B | 220,000 | 28.00 |
| 22-Feb | Multi Arc In | Kabra Seepra | B | 200,000 | 27.97 |
| 22-Feb | Multi Arc In | Sunidhi Securities and Finance Ltd | S | 282,500 | 28.00 |
| 22-Feb | Neocorp Inte | Navmee Securities Pvt Ltd | S | 47,000 | 59.00 |
| 22-Feb | Pioner Embro | Withal Commercial Pvt Ltd | B | 80,000 | 178.42 |
| 22-Feb | Pioner Embro | Santosh Industries Limited | S | 51,668 | 177.95 |
| 22-Feb | Pioner Embro | Maryada Barter Pvt Ltd | S | 120,000 | 178.20 |
| 22-Feb | Prithvi Info | Chandra Fin. Serv. Pvt. Ltd | B | 99,731 | 275.31 |
| 22-Feb | Suave Hotel | Navmee Securities Pvt Ltd | S | 30,000 | 36.09 |

Source: BSE

Gainers & Losers

Nifty Gainers & Losers

| | Price (Rs) | % change | Index points | Volume (mn) |
|--------------------|------------|----------|--------------|-------------|
| Gainers | | | | |
| National Aluminium | 416 | 3.5 | 1.6 | 0.5 |
| Cipla | 199 | 5.3 | 1.4 | 1.3 |
| SAIL | 239 | 0.7 | 1.3 | 11.7 |
| Losers | | | | |
| Reliance Ind | 2,434 | (2.5) | (15.6) | 2.0 |
| ICICI Bank | 1,100 | (3.6) | (8.0) | 2.0 |
| SBI | 2,114 | (3.0) | (7.1) | 0.7 |

Source: Bloomberg

Forthcoming events

COMPANY/MARKET

| Date | Event |
|--------|---|
| 25-Feb | IRB Infrastructure Developments listing on BSE & NSE; Tulsu Extrusions listing on BSE & NSE; Pfizer to announce 4th quarter earnings and dividend |
| 26-Feb | India to present Railway budget for the year 2008-09 Jindal Saw to announce earnings and dividend |
| 27-Feb | Alfa Laval India to announce earnings and dividend; Bharat Forge to consider proposal for fund raising plans |
| 28-Feb | India to announce Economic Survey for year ending March, 2008 |
| 29-Feb | India to unveil Federal budget for the year 2008-09 |

Source: Bloomberg

Research Team

| Name | Sector | Tel No | E-mail id |
|-------------------|-------------------------------|------------------|-----------------------------|
| Dipen Shah | IT, Media, Telecom | +91 22 6634 1376 | dipen.shah@kotak.com |
| Sanjeev Zarbade | Capital Goods, Engineering | +91 22 6634 1258 | sanjeev.zarbade@kotak.com |
| Teena Virmani | Construction, Cement, Mid Cap | +91 22 6634 1237 | teena.virmani@kotak.com |
| Awadhesh Garg | Pharmaceuticals, Hotels | +91 22 6634 1406 | awadhesh.garg@kotak.com |
| Apurva Doshi | Logistics, Textiles, Mid Cap | +91 22 6634 1366 | doshi.apurva@kotak.com |
| Saurabh Gurnurkar | IT, Media, Telecom | +91 22 6634 1273 | saurabh.gurnurkar@kotak.com |
| Saurabh Agrawal | Metals, Mining | +91 22 6634 1291 | agrawal.saurabh@kotak.com |
| Saday Sinha | Banking, Economy | +91 22 6634 1440 | saday.sinha@kotak.com |
| Rohit Ledwani | Retail | +91 22 6634 1507 | rohit.ledwani@kotak.com |
| Sarika Lohra | NBFCs | +91 22 6634 1480 | sarika.lohra@kotak.com |
| Chetan Shet | FMCG, Power | +91 22 6634 1382 | chetan.shet@kotak.com |
| Shrikant Chouhan | Technical analyst | +91 22 6634 1439 | shrikant.chouhan@kotak.com |
| Kaustav Ray | Editor | +91 22 6634 1223 | kaustav.ray@kotak.com |
| K. Kathirvelu | Production | +91 22 6634 1557 | k.kathirvelu@kotak.com |

Disclaimer

This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions.

This material is for the personal information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of clients of Kotak Securities Ltd. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients.

We have reviewed the report, and in so far as it includes current or historical information, it is believed to be reliable though its accuracy or completeness cannot be guaranteed. Neither Kotak Securities Limited, nor any person connected with it, accepts any liability arising from the use of this document. The recipients of this material should rely on their own investigations and take their own professional advice. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions -including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centers on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

Kotak Securities Limited has two independent equity research groups: Institutional Equities and Private Client Group. This report has been prepared by the Private Client Group. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Equities Research Group of Kotak Securities Limited.

We and our affiliates, officers, directors, and employees world wide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential conflict of interest with respect to any recommendation and related information and opinions.

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

No part of this material may be duplicated in any form and/or redistributed without Kotak Securities' prior written consent.

Registered Office: Kotak Securities Limited, Bakhtawar, 1st floor, 229 Nariman Point, Mumbai 400021 India.